Business
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025Enrollment in new Phase 2 SCLC trial to begin in Q2-Q3 2025, fully funded by the U.S. Veterans AdministrationAt-the-Market (ATM) program, initiated in March 2024, and related Form
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2n2B7OUZZNZTe8771hvug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":" ","length":48,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment in new Phase 2 SCLC trial to begin in Q2-Q3 2025, fully funded by the U.S. Veterans Administration","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"At-the-Market (ATM) program, initiated in March 2024, and related Form S-3, both fully utilized and no longer active","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with some patients on treatment for more than 17 months","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of approximately $25 million at end of Q1 2025, reinforcing financial stability","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":784,"olType":false},{"type":"text","content":"Boston (March 31, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP/WNT pathway inhibitor—today announced financial results for the year ended December 31, 2024, and provided a general business update.","length":342,"tagName":"p"},{"type":"text","content":"Thomas Jensen, Chief Executive Officer of Allarity Ther...